RB1 and prostate carcinoma: Alternatively, prostate cancer cells may have invoked mechanisms to bypass the cyclin D1 requirement (e.g. RB loss), thereby weakening the necessity to induce cyclin D1 accumulation (Lukas et al, 1995).